Adalimumab combo therapy for esophageal cancer before surgery
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of an immunotherapy drug (adalimumab), chemotherapy, and a targeted therapy pill (apatinib) before surgery for esophageal cancer that can be removed. The goal is to see if this mix helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with a type of esophageal cancer called squamous cell carcinoma.
- Your cancer is at a stage (II to IVA) where surgery is possible and has not spread to distant organs.
- You are between 18 and 75 years old.
- You are physically active enough to do light work (ECOG score 0 or 1).
- You do not have serious heart problems, an active autoimmune disease, or a history of another cancer in the last 5 years.
- You are not pregnant, breastfeeding, or currently being treated for hepatitis B.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining a type of immunotherapy (adebrelimab) with chemotherapy before surgery, for esophageal cancer that can be removed. The goal is to see if this combo helps shrink the tumor and improve outcomes.
This trial tests a combination of an immunotherapy drug (camrelizumab), chemotherapy, and another targeted drug (ivarmacitinib) before surgery for esophageal cancer. The goal is to see if this treatment can shrink the tumor before it is removed, potentially improving outcomes.
This trial tests whether giving a new immunotherapy drug (ivonescimab) along with standard chemotherapy before surgery can improve outcomes for people with resectable esophageal cancer. The goal is to shrink the tumor and increase the chance of successful surgery.
This trial tests a new approach for patients with a specific type of esophageal cancer that can be surgically removed. You would first receive a combination of an immunotherapy drug (adebrelimab) with chemotherapy and radiation, and then instead of immediate surgery, your doctor would monitor you closely to see if surgery is still needed. This may help some patients avoid surgery while keeping the cancer under control.
This trial tests a combination of three medicines (immunotherapy plus two chemotherapy drugs) given before surgery to shrink esophageal cancer. The goal is to make the tumor smaller and easier to remove completely, potentially improving the chance of a cure.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy, given before surgery, helps shrink esophageal cancer tumors and improves outcomes. It is for people with a specific type of esophageal cancer that has not spread widely.
Hear when a new Esophageal Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.